Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMV

IMV (IMV) Stock Price, News & Analysis

IMV logo

About IMV Stock (NASDAQ:IMV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.49
$0.91
52-Week Range
N/A
Volume
44,800 shs
Average Volume
233,607 shs
Market Capitalization
$9.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV Stock News Headlines

What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
Aquarius: Monthly horoscope November
See More Headlines

IMV Stock Analysis - Frequently Asked Questions

IMV Inc. (NASDAQ:IMV) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($1.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.30). The business earned $0.04 million during the quarter. IMV had a negative net margin of 11,547.42% and a negative trailing twelve-month return on equity of 12,695.41%.

IMV's stock reverse split on the morning of Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that IMV investors own include Pfizer (PFE), Nokia Oyj (NOK), NIO (NIO), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), VBI Vaccines (VBIV) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/11/2021
Today
4/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMV
Fax
N/A
Employees
97
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,990,000.00
Net Margins
-11,547.42%
Pretax Margin
-11,547.42%
Return on Equity
-12,695.41%

Debt

Sales & Book Value

Annual Sales
$330,000.00
Price / Cash Flow
N/A
Book Value
($0.69) per share
Price / Book
N/A

Miscellaneous

Free Float
11,673,000
Market Cap
$9.63 million
Optionable
Optionable
Beta
0.95
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:IMV) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners